Fast Track Immunotherapeutic Development with MuScreen™


High Throughput Syngeneic In Vivo Screen for Evaluating Immunotherapies

Next 12 model MuScreen:  Enroll By 9/15/2018

  • Evaluate TGI with the Syngeneic Efficacy Screening Panel of 6 or 12 models

  • Large-scale, staggered screening reduces variability from sources such as antibodies and mice

  • Improve efficiency and save study time by rapidly identifying markers or models

  • An effective and accurate way to find the right model - particularly for your combination studies

  • Benefit from multiple clients sharing the results of vehicle and other common groups significantly reducing both the number of animals needed and your associated costs

Choose MuScreen Over a Traditional In Vitro Study

  • Comprising of a predesignated syngeneic panel across a range of cancer types, built upon our collection of validated and well-characterized syngeneic models

  • You can leverage detailed model checkpoint inhibitor benchmarking data, as well as RNAseq and optional FACS analysis information

  • Models run on a large scale, preset schedule, with shared vehicle and common groups to improve efficiency, reproducibility, and cost-effectiveness

Request MuScreen Pricing